Descriptive epidemiology of cutaneous melanoma – A treasure for generating hypotheses

by Andreas Stang, Axel Hauschild
Published 2021-03-01

Feasibility of assessing utilities with a single-item standard gamble questionnaire in patients with melanoma

by Christine Blome, Katharina C. Kähler, Tobias Wagner, Axel Hauschild, Matthias Augustin
Published 2021-08-01

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase

by Valerie Glutsch, Teresa Amaral, Claus Garbe, Kai-Martin Thoms, Peter Mohr, Axel Hauschild, Bastian Schilling
Published 2020-06-01

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma

by Dirk Schadendorf, Paul Nghiem, Shailender Bhatia, Axel Hauschild, Philippe Saiag, Lisa Mahnke, Subramanian Hariharan, Howard L. Kaufman
Published 2017-10-01

The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans.

by Karin Loser, Thomas Brzoska, Vinzenz Oji, Matteo Auriemma, Maik Voskort, Verena Kupas, Lars Klenner, Cornelius Mensing, Axel Hauschild, Stefan Beissert, Thomas A Luger
Published 2010-01-01

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled a...

by Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun, Brigitte Dréno
Published 2020-08-01

Willingness to pay for a cure of low-risk melanoma patients in Germany.

by Matthias Augustin, Christine Blome, Andrea Forschner, Ralf Gutzmer, Axel Hauschild, Lucie Heinzerling, Elisabeth Livingstone, Carmen Loquai, Dirk Schadendorf, Jochen Utikal, Tobias Wagner, Sophia Wilden, Katharina C Kähler
Published 2018-01-01

433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial...

by Min Yi, Celeste Lebbe, Parminder Singh, Omid Hamid, Jason Chesney, Igor Puzanov, Mohammed Milhem, Merrick Ross, Janice Mehnert, Theodore Logan, Philip Friedlander, Frances Collichio, Claus Garbe, John Glaspy, Axel Hauschild, Wendy Snyder
Published 2020-11-01

Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective

by Tanja B. Jutzi, Eva I. Krieghoff-Henning, Tim Holland-Letz, Jochen Sven Utikal, Jochen Sven Utikal, Axel Hauschild, Dirk Schadendorf, Wiebke Sondermann, Stefan Fröhling, Achim Hekler, Max Schmitt, Roman C. Maron, Titus J. Brinker
Published 2020-06-01

Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.

by Lisa Zimmer, Julia Vaubel, Peter Mohr, Axel Hauschild, Jochen Utikal, Jan Simon, Claus Garbe, Rudolf Herbst, Alexander Enk, Eckhart Kämpgen, Elisabeth Livingstone, Leonie Bluhm, Rainer Rompel, Klaus G Griewank, Michael Fluck, Bastian Schilling, Dirk Schadendorf
Published 2015-01-01

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

by Joanna Mangana, Phil F Cheng, Katja Schindler, Benjamin Weide, Ulrike Held, Anna L Frauchiger, Emanuella Romano, Katharina C Kähler, Sima Rozati, Markus Rechsteiner, Holger Moch, Olivier Michielin, Claus Garbe, Axel Hauschild, Christoph Hoeller, Reinhard Dummer, Simone M Goldinger
Published 2015-01-01

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

by Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Published 2019-04-01

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

by Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Published 2017-05-01

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

by Marcus Butler, Rogerio Neves, Lisa Licitra, Israel Lowy, Zeynep Eroglu, Karl Lewis, Leonel Hernandez-Aya, Axel Hauschild, Emmanuel Okoye, Siyu Li, Jean-Francois Baurain, Oliver Bechter, Ketty Peris, Aleksandar Sekulic, Alexander Stratigos, Lara Dunn, Anne Lynn Chang, Michael Migden, Kosalai Mohan, Ebony Coates, Emily Ruiz, Frank Seebach, David Weinreich, George Yancopoulos, Timothy Bowler, Matthew Fury
Published 2020-11-01

Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review

by Julia Höhn, Achim Hekler, Eva Krieghoff-Henning, Jakob Nikolas Kather, Jochen Sven Utikal, Friedegund Meier, Frank Friedrich Gellrich, Axel Hauschild, Lars French, Justin Gabriel Schlager, Kamran Ghoreschi, Tabea Wilhelm, Heinz Kutzner, Markus Heppt, Sebastian Haferkamp, Wiebke Sondermann, Dirk Schadendorf, Bastian Schilling, Roman C Maron, Max Schmitt, Tanja Jutzi, Stefan Fröhling, Daniel B Lipka, Titus Josef Brinker
Published 2021-07-01

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.

by Caroline J Voskens, Simone M Goldinger, Carmen Loquai, Caroline Robert, Katharina C Kaehler, Carola Berking, Tanja Bergmann, Clemens L Bockmeyer, Thomas Eigentler, Michael Fluck, Claus Garbe, Ralf Gutzmer, Stephan Grabbe, Axel Hauschild, Rüdiger Hein, Gheorghe Hundorfean, Armin Justich, Ullrich Keller, Christina Klein, Christine Mateus, Peter Mohr, Sylvie Paetzold, Imke Satzger, Dirk Schadendorf, Marc Schlaeppi, Gerold Schuler, Beatrice Schuler-Thurner, Uwe Trefzer, Jens Ulrich, Julia Vaubel, Roger von Moos, Patrik Weder, Tabea Wilhelm, Daniela Göppner, Reinhard Dummer, Lucie M Heinzerling
Published 2013-01-01

Correction: Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients

by Lisa Zimmer, Serigne Lo, Caroline Robert, John Haanen, Ines Pires da Silva, Reinhard Dummer, Michael Manos, Joanna Mangana, Marcus O Butler, Richard D Carvajal, Alon Vaisman, Christian Posch, F Stephen Hodi, Paola Queirolo, Axel Hauschild, Christian U Blank, Maria Grazia Vitale, Karijn P M Suijkerbuijk, Alexander M Menzies, Aljosja Rogiers, Chiara Tentori, Joseph M Grimes, Megan H Trager, Sharon Nahm, Peter Bowling, Neha Papneja, April A N Rose, Jessica S W Borgers, Severine Roy, Thiago Pimentel Muniz, Tim Cooksley, Jeremy Lupu, Samuel D Saibil, Michael Erdmann, Laura Pala, Ryan J Sullivan, Wilson H Miller Jr, Osama E Rahma, Paul C Lorigan
Published 2021-01-01

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

by Lisa Zimmer, Serigne Lo, Caroline Robert, John Haanen, Ines Pires da Silva, Reinhard Dummer, Michael Manos, Joanna Mangana, Marcus O Butler, Richard D Carvajal, Alon Vaisman, Christian Posch, F Stephen Hodi, Paola Queirolo, Axel Hauschild, Christian U Blank, Maria Grazia Vitale, Karijn P M Suijkerbuijk, Alexander M Menzies, Aljosja Rogiers, Chiara Tentori, Joseph M Grimes, Megan H Trager, Sharon Nahm, Peter Bowling, Neha Papneja, April A N Rose, Jessica S W Borgers, Severine Roy, Thiago Pimentel Muniz, Tim Cooksley, Jeremy Lupu, Samuel D Saibil, Michael Erdmann, Laura Pala, Ryan J Sullivan, Wilson H Miller Jr, Osama E Rahma, Paul C Lorigan
Published 2021-01-01